Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

J Biol Chem. 2015 Oct 23;290(43):25850. doi: 10.1074/jbc.A115.553818.
No abstract available

Publication types

  • Published Erratum